Y Mabs Therapeutics Stock Investor Sentiment

YMAB Stock  USD 5.19  0.37  6.65%   
About 79 percent of Y MAbs' investors are selling. The analysis of the overall investor sentiment regarding Y mAbs Therapeutics suggests that quite a large number of traders are terrified. The current market sentiment, together with Y MAbs' historical and current headlines, can help investors time the market. In addition, many technical investors use Y mAbs Therapeutics stock news signals to limit their universe of possible portfolio assets.
  

Y MAbs Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Y MAbs can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over six months ago at news.google.com         
Disposition of 1682 shares by Susan Smith of Y MAbs at 16.55 subject to Rule 16b-3
Google News at Macroaxis
over six months ago at www.macroaxis.com         
Acquisition by Rajah Vignesh of 35700 shares of Y MAbs subject to Rule 16b-3
Macroaxis News
over six months ago at simplywall.st         
The 7.8 percent return this week takes Y-mAbs Therapeutics shareholders one-year gains to 169
Simply Wall St News at Macroaxis
over six months ago at news.google.com         
Bailard Inc. Acquires Shares of 16900 Y-mAbs Therapeutics, Inc. - Defense World
Google News at Macroaxis
over six months ago at news.google.com         
Y-mAbs Therapeutics Board Member Dr. Ber Announces Resignation - TipRanks.com - TipRanks
Google News at Macroaxis
over six months ago at globenewswire.com         
Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024
Macroaxis News: globenewswire.com
over six months ago at benzinga.com         
Y-mAbs to Present at 2024 ASCO Annual Meeting
benzinga news
over six months ago at news.google.com         
Y-mAbs Therapeutics Stock Price Up 7 percent - MarketBeat
Google News at Macroaxis
over six months ago at finance.yahoo.com         
Y-mAbs Therapeutics rises 9.6 percent this week, taking one-year gains to 161
Yahoo News
over six months ago at news.google.com         
Sapient Capital LLC Acquires New Shares in Y-mAbs Therapeutics, Inc. - Defense World
Google News at Macroaxis
over six months ago at news.google.com         
Y-mAbs Therapeutics Shares Down 3.3 percent - MarketBeat
Google News at Macroaxis
over six months ago at investing.com         
BMO maintains Outperform rating on Y-mAbs stock
Investing News at Macroaxis
over six months ago at simplywall.st         
Y-mAbs Therapeutics Insiders Who Sold Avert US91m Market Cap Dip
Simply Wall St News at Macroaxis
over six months ago at news.google.com         
Y-mAbs Therapeutics Shares Down 3.2 percent - MarketBeat
Google News at Macroaxis
over six months ago at news.google.com         
Y-mAbs Therapeutics Shares Gap Down to 16.19 - MarketBeat
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Y MAbs that are available to investors today. That information is available publicly through YMAB media outlets and privately through word of mouth or via YMAB internal channels. However, regardless of the origin, that massive amount of YMAB data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Y MAbs news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Y MAbs relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Y MAbs' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Y MAbs alpha.

Y MAbs Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Acquisition by Wg Biotech Aps of 30671 shares of Y MAbs at 5.8125 subject to Rule 16b-3
12/06/2024
2
Insider Trading
01/06/2025
3
Y-mAbs Provides Strategic Business Update and 2025 Priorities
01/10/2025
4
Acquisition by Larocca John of 21500 shares of Y MAbs subject to Rule 16b-3
01/17/2025
5
Y-mAbs Therapeutics Finding Direction Through The Murk Of Clinical Trials - Seeking Alpha
01/24/2025
6
Y-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the ...
01/31/2025
7
YmAbs Therapeutics Loses -26.93 percent in 4 Weeks, Heres Why a Trend Reversal May be Around the Corner
02/03/2025
8
Y-mAbs to Present at the Oppenheimer 35 Annual Life Sciences Conference
02/06/2025
9
YMAB Stock Touches 52-Week Low at 5.69 Amid Market Challenges - MSN
02/11/2025
10
Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025
02/20/2025
11
Y-mAbs Therapeutics to Release Earnings on Tuesday - MarketBeat
02/27/2025

Complementary Tools for YMAB Stock analysis

When running Y MAbs' price analysis, check to measure Y MAbs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Y MAbs is operating at the current time. Most of Y MAbs' value examination focuses on studying past and present price action to predict the probability of Y MAbs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Y MAbs' price. Additionally, you may evaluate how the addition of Y MAbs to your portfolios can decrease your overall portfolio volatility.
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Global Correlations
Find global opportunities by holding instruments from different markets
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance